Alyssa Monsen is a seasoned lawyer specializing in life sciences patent litigation.

Her legal practice is concentrated in U.S. federal district and appellate courts, as well as inter partes review proceedings before the Patent Trial and Appeal Board. Alyssa has a robust track record of representing innovator pharmaceutical companies in high-stakes litigation, with a focus on therapies related to oncology, ophthalmology, and infectious diseases.

Her experience spans all phases of patent litigation, encompassing pre-litigation strategic planning, trial, and appeals to the Federal Circuit. Additionally, Alyssa is skilled in advising clients on patent portfolio assessment, due diligence, and strategies for international patent enforcement.

Alyssa has been recognized by Super Lawyers as a Rising Star since 2017, and Best Lawyers added her to its 2023 Ones to Watch list in the areas of Intellectual Property and Patent Litigation.

Before her legal career, Alyssa served as a strategy consultant for pharmaceutical companies at Computer Sciences Corporation. She also gained valuable experience in market research, working with a firm that serves hedge funds and institutional investors, focusing on the pharmaceutical, biotechnology, medical device, and dental sectors.

Representative Experience

• Trial and appeal counsel for Johnson & Johnson subsidiary Janssen Pharmaceuticals in patent infringement suits filed under the Hatch-Waxman Act and inter partes review proceedings involving blockbuster prostate cancer drug, Zytiga®.
• Litigation counsel for Genetech, Gilead, and Hoffman-La Roche in a patent infringement suit filed under the Hatch-Waxman Act involving blockbuster influenza drug, Tamiflu®.
• Trial and appeal counsel for plaintiffs in patent infringement suits filed under the Hatch-Waxman Act involving topical ophthalmic antibiotic, AzaSite®.